Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
08 févr. 2023 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis
06 janv. 2023 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
As previously reported, resmetirom demonstrated improvements in NASH and liver fibrosis on liver biopsies, the primary endpoints of the MAESTRO-NASH trialA supportive analysis using consensus reads of...
Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program
21 déc. 2022 16h15 HE
|
Madrigal Pharmaceuticals, Inc.
$259 Million in Equity Securities Sales and $50 Million in Additional Debt Financing CapacityMadrigal intends to submit a new drug application for resmetirom in the first half of 2023 CONSHOHOCKEN,...
Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis
19 déc. 2022 07h00 HE
|
Madrigal Pharmaceuticals, Inc.
In MAESTRO-NASH, a 52-week serial liver biopsy Phase 3 study in more than 950 patients, resmetirom achieved both primary endpoints and potentially clinically meaningful effects with both daily oral...
Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NASH Study of Resmetirom on Monday, December 19th
18 déc. 2022 16h00 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Dec. 18, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Madrigal Pharmaceuticals Provides an Overview of Upcoming Resmetirom Data Presentations and Reports 2022 Third Quarter Financial Results
03 nov. 2022 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
Two resmetirom oral abstracts to be presented at the AASLD Liver Meeting®: Phase 3 MAESTRO-NAFLD-1 data demonstrate the potential of resmetirom for the treatment of patients with compensated NASH...
Madrigal Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
07 sept. 2022 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis
31 août 2022 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results
04 août 2022 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
Madrigal remains on track to announce topline data from the Phase 3 MAESTRO-NASH biopsy study in the fourth quarter CONSHOHOCKEN, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals,...
Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™
25 juin 2022 09h00 HE
|
Madrigal Pharmaceuticals, Inc.
Late-breaking data from the double-blind portion of the noninvasive Phase 3 MAESTRO NAFLD-1 study show resmetirom to be safe and well-tolerated and to reduce liver fat, fibrosis measures on FibroScan...